Search

Displaying results 2491 - 2500 of 10000 in total
  1. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L3344] On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersProducts: BRAFTOVI® 75 MG CÁPSULAS, BRAFTOVİ 75 MG SERT KAPSÜL, 42 ADET
  2. Drug

    Orismilast

    go.drugbank.com/drugs/DB19042
    Investigational

    Orismilast is under investigation in clinical trial NCT05190419 (Study to Assess the Efficacy and Safety of Orismilast in Psoriasis).

    Synonyms: 2-(3,5-dichloro-1-oxido-4-pyridinyl)-1-(7-(difluoromethoxy)-2',3',5',6'-tetrahydro-1',1'-dioxidospiro(1,3-benzodioxole-2,4'-(4h)thiopyran)-4-yl)ethanone
  3. Drug

    Metacavir

    go.drugbank.com/drugs/DB19084
    Investigational

    Metacavir is under investigation in clinical trial NCT02965859 (The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B).

    Synonyms: ((2s,5r)-5-(2-amino-6-methoxy-purin-9-yl)tetrahydrofuran-2-yl)methanol, 2',3'-dideoxy-6-o-methylguanosineCategories: Heterocyclic Compounds, 2-Ring
  4. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
  5. Drug

    Lartesertib

    go.drugbank.com/drugs/DB19045
    Investigational

    Lartesertib is under investigation in clinical trial NCT06433219 (Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (Ddriver EOC 302)).

    Synonyms: 2H-Imidazo[4,5-c]quinolin-2-one, 8-(1,3-dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxy-4-pyridinyl)-1,3-dihydro-7-methoxy-3-methyl-, (1S)-, 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(3-fluoro-5-methoxy-4-pyridinyl)-1,3-dihydro-7-methoxy-3-methyl-2h-imidazo(4,5-c)quinolin-2-one
  6. Drug

    Gandotinib

    go.drugbank.com/drugs/DB13040
    Investigational

    Gandotinib has been used in trials studying the treatment of Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders, among others.

    Synonyms: 3-(4-CHLORO-2-FLUOROBENZYL)-2-METHYL-N-(5-METHYL-1H-PYRAZOL-3-YL)-8- (MORPHOLINOMETHYL)IMIDAZO(1,2-B)PYRIDAZIN-6-AMINE, IMIDAZO(1,2-B)PYRIDAZIN-6-AMINE, 3-((4-CHLORO-2-FLUOROPHENYL)METHYL)-2-METHYL-N-(5- METHYL-1H-PYRAZOL-3-YL)-8-(4-MORPHOLINYLMETHYL)-Categories: Heterocyclic Compounds, 1-Ring, Janus Kinase 2, antagonists & inhibitors
  7. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. … [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage

    Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: IMFINZI® 50 MG/ML CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN, IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML
  8. Drug

    Gavorestat

    go.drugbank.com/drugs/DB16707
    Investigational

    Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).

    Synonyms: 2-(4-Oxo-3-((5-(Trifluoromethyl)Benzo[D]Thiazol-2-Yl)Methyl)-3,4-Dihydrothieno[3,4-D]Pyridazin-1-Yl)Acetic Acid
  9. Drug

    {(4Z)-2-[(1R,2R)-1-Amino-2-hydroxypropyl]-4-[(4-amino-1H-indol-3-yl)methylene]-5-oxo-4,5-dihydro-1H-imidazol-1-yl}acetic acid

    go.drugbank.com/drugs/DB01641
    Experimental

    Synonyms: {(4Z)-2-[(1R,2R)-1-Amino-2-hydroxypropyl]-4-[(4-amino-1H-indol-3-yl)methylene]-5-oxo-4,5-dihydro-1H-imidazol-1-yl}acetic acid
  10. Drug

    N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE

    go.drugbank.com/drugs/DB07019
    Experimental

    Synonyms: N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE